Angiotensin II type 1 receptor 1166A/C polymorphism in association with blood pressure response to exogenous angiotensin II

What Was Tested

Researchers studied Angiotensin II in the context of low blood pressure and orthostatic hypotension in this clinical trial publication.

The angiotensin II type 1 receptor (AT1R) 1166A/C polymorphism is reported to be implicated in cardiovascular diseases.

Who Took Part

PubMed indexes the participants as adults, both men and women.

Thirteen normotensive, healthy adults (six with the 1166A/A polymorphism and seven with 1166A/C) were enrolled in this clinical study.

How the Study Was Run

BP was measured serially before and at the end of each rate of angiotensin II infusion.

Plasma concentration-time profiles of valsartan were established over a 24-h period.

What Was Measured

Topics PubMed links to this paper include Angiotensin II, Angiotensin II Type 1 Receptor Blockers, Blood Pressure, Gene Frequency, Genotype, Polymorphism, Single Nucleotide and Receptor, Angiotensin, Type 1.

What This Means in Plain Language

This is a clinical trial of Angiotensin II in people with low blood pressure and orthostatic hypotension.

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2007 (European journal of clinical pharmacology), a journal based in Germany.

More context: the Angiotensin II compound page, Low blood pressure and orthostatic hypotension research.